Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Colorcon
Daiichi Sankyo
Fish and Richardson
Baxter
McKesson
Boehringer Ingelheim
US Department of Justice
Accenture

Generated: May 21, 2018

DrugPatentWatch Database Preview

SANOREX Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Sanorex patents expire, and what generic alternatives are available?

Sanorex is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in SANOREX is mazindol. Additional details are available on the mazindol profile page.
Summary for SANOREX
Drug patent expirations by year for SANOREX
Medical Subject Heading (MeSH) Categories for SANOREX
Synonyms for SANOREX
(+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol
[3H]-mazindol
[3H]MAZINDOL
22232-71-9
232M719
3H-Imidazo(2,1-a)isoindol-5-ol, 2,5-dihydro-5-(4-chlorophenyl)-
3H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-
3H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-, (+-)-
3H-Imidazo(2,1-a)isoindol-5-ol, 5-(p-chlorophenyl)-2,5-dihydro-
3H-Imidazo[2,1-a]isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-
3H-Imidazo[2,1-a]isoindol-5-ol, 5-(p-chlorophenyl)-2,5-dihydro-
5-(4-Chloro-phenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol
5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole
5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole
5-(4-chlorophenyl)-2,3-dihydro-5H-imidazo [2,1-a]isoindol-5-ol
5-(4-chlorophenyl)-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ol
5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol
5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol
5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol #
5-(4-chlorophenyl)-2H,3H,5H-imidazo[2,1-a]isoindol-5-ol
5-(4-Chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol
5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol
5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol
5-[4-CHLOROPHENYL]-2,5-DIHYDRO-3H-IMIDAZO[2,1-A]IS
5-Hydroxy-5-p-chlorophenyl-2,3-dihydro-5H-imidazo[2,1-a]isoindole
5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol
5-Thiophen-2-yl-2,3,5,6-tetrahydro-imidazo[2,1-a]isoquinolin-5-ol
5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro
5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro-
A816031
AC1L1H8E
AJ-190/40105266
AK-93028
AKOS015895573
AN 448
AN-448
AN-6542
AN448
ANW-63061
BDBM50005536
BRN 0546547
C-17933
CC-30162
CCRIS 3152
CHEBI:6702
CHEMBL781
CTK8B9778
D00367
D01JRD
D0H8QL
DB00579
DEA No. 1605
Diestet
Dimagrir
DTXSID1023237
EINECS 244-857-0
FT-0630484
GTPL4591
GTPL4797
HSDB 3112
HY-15279
I06-0844
LS-77865
Magrilon
Mazanor
Mazanor (TN)
Mazanor|||Sanorex
Mazildene
mazindol
Mazindol (JAN/USP/INN)
Mazindol [USAN:BAN:INN]
Mazindol Medix Brand
Mazindol Novartis Brand
Mazindol Searle Brand
Mazindol Wyeth Brand
Mazindol, >=98% (TLC), powder
Mazindol, United States Pharmacopeia (USP) Reference Standard
Mazindole
Mazindolo
Mazindolum
Mazindolum [INN-Latin]
Medix Brand of Mazindol
MFCD00864480
MLS003899228
Novartis Brand of Mazindol
PL043555
PL050764
S 42548
SA 42-548
SAH 42548
SaH-42548
Sanjorex
SANOREX (TN)
SC-17288
SCHEMBL27849
Searle Brand of Mazindol
SMR000238174
Solucaps
TC-151806
Terenac
Teronac
Teronak
W-5129
Wyeth Brand of Mazindol
ZPXSCAKFGYXMGA-UHFFFAOYSA-N

US Patents and Regulatory Information for SANOREX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis SANOREX mazindol TABLET;ORAL 017247-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis SANOREX mazindol TABLET;ORAL 017247-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for SANOREX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis SANOREX mazindol TABLET;ORAL 017247-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis SANOREX mazindol TABLET;ORAL 017247-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Express Scripts
Boehringer Ingelheim
Fuji
Cipla
Julphar
Healthtrust
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.